Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 3275 of 3499 entries
View as:

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01468818 Org: User:
Start: 09/30/11 End: 08/31/13 Due: 08/31/14

Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00132028 Org: User:
Start: 09/30/05 End: 05/31/09 Due: 05/31/10

CC-5013 in Treating Patients With Recurrent Glioma

Phase: N/A Priority: Normal
NCT ID: NCT00036894 Org: User:
Start: 03/31/02 End: - Due: -

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Phase: N/A Priority: Normal
NCT ID: NCT03842228 Org: User:
Start: 11/21/19 End: 03/17/26 Due: 03/17/27

Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05185947 Org: User:
Start: 10/13/22 End: 04/04/25 Due: 04/04/26

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Phase: N/A Priority: Normal
NCT ID: NCT04439357 Org: User:
Start: 02/25/16 End: 12/31/25 Due: 12/31/26

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04671667 Org: User:
Start: 04/27/21 End: 02/28/26 Due: 02/28/27

Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00040768 Org: User:
Start: 04/30/02 End: - Due: -

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00046917 Org: User:
Start: 07/31/02 End: - Due: -

Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain

Phase: N/A Priority: Normal
NCT ID: NCT00032097 Org: User:
Start: 04/30/02 End: - Due: -

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04817254 Org: User:
Start: 12/08/21 End: 12/31/26 Due: 12/31/27

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT03436732 Org: User:
Start: 02/28/18 End: 04/30/19 Due: 04/30/20

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00942877 Org: User:
Start: 07/18/09 End: 12/31/24 Due: 12/31/25

An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...

Phase: N/A Priority: Normal
NCT ID: NCT00924092 Org: User:
Start: 03/13/09 End: 08/02/12 Due: 08/02/13

HGS-ETR2 to Treat Children With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00428272 Org: User:
Start: 12/04/06 End: 10/09/15 Due: 10/09/16

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00478140 Org: User:
Start: 05/31/07 End: 11/30/11 Due: 11/30/12

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03233711 Org: User:
Start: 07/05/18 End: 12/31/25 Due: 12/31/26

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02642042 Org: User:
Start: 07/18/16 End: 03/19/26 Due: 03/19/27

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05035407 Org: User:
Start: 03/08/22 End: 04/05/26 Due: 04/05/27

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01168232 Org: User:
Start: 09/07/10 End: 11/26/13 Due: 11/26/14

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02257528 Org: User:
Start: 05/18/15 End: 03/17/26 Due: 03/17/27

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06649812 Org: User:
Start: 07/07/25 End: 09/01/27 Due: 09/01/28

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03775265 Org: User:
Start: 06/03/19 End: 06/01/27 Due: 06/01/28

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT00459862 Org: User:
Start: 03/31/07 End: 05/31/13 Due: 05/31/14

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02446600 Org: User:
Start: 03/28/16 End: 08/23/25 Due: 08/23/26